A Phase 3, Double-Blind, Randomized, Placebo-Controlled study of Baricitinib to delay Stage 3 Type 1 Diabetes in at-risk participants aged ≥1 to <36 years. (BARICADE-DELAY) (I4V-MC-JAJJ (BARICADE-DELAY))

Principal Investigator

Dr Rachel Besser

Contact us

Email: childrensresearch@ouh.nhs.uk

IRAS number

1012740